Synthesis, structure activity relationships and biological activity evaluation of novel spirocyclic thiazolidin-4-ones as potential anti-breast cancer and epidermal growth factor receptor inhibitors
Author's Department
Chemistry Department
Find in your Library
https://doi.org/10.1055/s-0033-1351314
Document Type
Research Article
Publication Title
Drug Research
Publication Date
1-1-2014
doi
10.1055/s-0033-1351314
Abstract
A series of triazaspiro[4.5]dec-8-ene benzylidine derivatives containing thiazolidinone ring system (6-18) have been designed, synthesized and their biological activities evaluated as potential epidermal growth factor receptor inhibitors. Among them, 9-amino-2-(4-nitrobenzylidene)-3-oxo-4-phenyl-7-thioxo- 1-thia-4,6,8-triazaspiro[4.5]dec-8-ene-10-carbonitrile (18) displayed the most potent inhibitory activity (IC50=6.355 μM). Antiproliferative assay results indicated that compound 18 exhibited moderate antiproliferative activity against MCF-7 cell line in vitro; with GI50 value of 30.6 μM. In addition, compounds 7 and 15 displayed the highest antiproliferative activity at a common GI50 value of 10.8 μM. Docking simulation was performed to determine the probable binding model and to pursuit information regarding the activity of compound 18. Based on the preliminary results, compound 18 could be used as an attractive building block for designing potential epidermal growth factor receptor inhibitors. © Georg Thieme Verlag KG Stuttgart New York.
First Page
23
Last Page
30
Recommended Citation
APA Citation
Fleita, D. H.
Sakka, O. K.
&
Mohareb, R.
(2014). Synthesis, structure activity relationships and biological activity evaluation of novel spirocyclic thiazolidin-4-ones as potential anti-breast cancer and epidermal growth factor receptor inhibitors. Drug Research, 64(1), 23–30.
10.1055/s-0033-1351314
https://fount.aucegypt.edu/faculty_journal_articles/1872
MLA Citation
Fleita, Daisy, et al.
"Synthesis, structure activity relationships and biological activity evaluation of novel spirocyclic thiazolidin-4-ones as potential anti-breast cancer and epidermal growth factor receptor inhibitors." Drug Research, vol. 64,no. 1, 2014, pp. 23–30.
https://fount.aucegypt.edu/faculty_journal_articles/1872